Treatment duration of community-acquired pneumonia due to Legionella pneumophila: where do we stand? - 22/07/26
, Michelle Saliba a, Laurence Maulin c, Yves Welker bAbstract |
Introduction |
While recent guidelines for treatment of community-acquired pneumonia (CAP) recommend short antibiotic duration, evidence regarding Legionella pneumophila pneumonia remains limited.
Methods |
We conducted a narrative review of studies identified via PubMed and Embase, including randomized trials, observational studies and meta-analyses assessing treatment duration and outcomes.
Results |
No randomized trials specifically address legionellosis. Data from CAP consistently support short courses (≤5–7 days), even for atypical pathogens. Observational studies suggest a clinical course similar to that applied for typical CAP, with rapidly attained stability and short intravenous treatment durations. Meta-analyses show no differences in clinical cure, relapse, or mortality between short and long regimens, with fewer adverse events occurring in shorter courses.
Conclusion |
While short-course therapy appears appropriate for legionellosis (3–5 days for non-severe cases, 10–14 days for severe cases and/or immunocompromised patients), prospective studies remain needed.
Le texte complet de cet article est disponible en PDF.Highlights |
• | As of yet, no randomized trials specifically addressing treatment duration for Legionella pneumophila pneumonia have been carried out. |
• | Evidence from CAP studies supports short antibiotic courses (≤5–7 days), including for atypical pathogens. |
• | The clinical evolution of legionellosis appears similar to that of typical CAP. |
• | For severe cases, treatment durations of 10–14 days seem sufficient. |
• | Based on the available evidence, shorter antibiotic regimens may be appropriate for legionellosis. |
Keywords : Legionella pneumophila , Legionnaires' disease, Antibiotic duration, Community-acquired pneumonia, Short-course therapy
Plan
Vol 56 - N° 5
Article 105299- juillet 2026 Retour au numéro
Article précédent
- Impact of discontinuing antibiotic susceptibility testing for Enterococcus faecalis-positive urine cultures on antibiotic prescriptions
- Guillaume Baronnet, Elodie Jeanbert, Emeric Emond, Philippe Cailloux, Nejla Aïssa, Nathalie Thilly, Maïa Simon, Alexandre Charmillon
- Real-world use of Dalbavancin for vascular graft and Endograft infections
- C. Leanza, M. Ascione, M. Carnevalini, F. Faccenna, F. Miceli, A. Di Girolamo, L. Di Marzo, C. Mastroianni, W. Mansour, A. Oliva
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?